ERASCA INC. - COMMON STOCK

Erasca Presents Promising Preliminary Phase 1/1b Monotherapy Data for ERAS-007 ERK and ERAS-601 SHP2 Inhibitors Supporting Ongoing and Future Combination Trials

07 Sep 2022 16:05:00 By Nasdaq GlobeNewswire

Erasca to Host R&D Day with KOL Dr. David Hong on Lead Clinical Programs ERAS-007 and ERAS-601 in Advanced Solid Tumors

24 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca and MD Anderson Announce Strategic Research and Development Collaboration in RAS/MAPK-Driven Cancers

23 Aug 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Reports Second Quarter 2022 Financial Results and Business Updates

11 Aug 2022 16:05:04 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

18 Jul 2022 08:00:00 By Nasdaq GlobeNewswire

Erasca to Present at the 2022 Jefferies Healthcare Conference

03 Jun 2022 09:00:00 By Nasdaq GlobeNewswire

Erasca Announces Trial to Evaluate ERAS-007 in Combination with KRAS G12C Inhibitor in KRAS-Driven Cancers

02 Jun 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Strengthens Clinical and Commercial Leadership with Three Key Appointments

25 May 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Reports First Quarter 2022 Financial Results and Business Updates

12 May 2022 16:01:00 By Nasdaq GlobeNewswire

Erasca to Present at the Bank of America Securities 2022 Healthcare Conference

03 May 2022 08:00:02 By Nasdaq GlobeNewswire

Erasca Appoints Jean Liu to its Board of Directors

27 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Presents Compelling Preclinical Data Supporting Clinical Development of Potentially Best-In-Class Programs ERAS-007, ERAS-601, and ERAS-3490 at 2022 AACR Annual Meeting

12 Apr 2022 16:01:00 By Nasdaq GlobeNewswire

Erasca To Host Investor Event with Leading KOL Dr. Scott Kopetz on Therapeutic Opportunities in Cancers Driven by the RAS/MAPK Pathway

06 Apr 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Reports Fourth Quarter 2021 Financial Results and Business Updates

24 Mar 2022 16:05:01 By Nasdaq GlobeNewswire

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination

10 Mar 2022 08:00:03 By Nasdaq GlobeNewswire

Erasca Announces Six Poster Presentations at the 2022 AACR Annual Meeting

08 Mar 2022 16:31:00 By Nasdaq GlobeNewswire

Erasca to Present at the Guggenheim Healthcare Talks 2022 Oncology Day

03 Feb 2022 08:00:01 By Nasdaq GlobeNewswire

Erasca Strengthens Leadership Team with Two Key Executive Appointments

18 Jan 2022 08:00:03 By Nasdaq GlobeNewswire

Erasca to Present at the 40th Annual J.P. Morgan Healthcare Conference

04 Jan 2022 08:00:02 By Nasdaq GlobeNewswire

Erasca Announces FDA Clearance of IND Application for ERAS-801 in Glioblastoma Multiforme and Collaboration with GCAR for Potential Inclusion in GBM AGILE Clinical Trial

17 Dec 2021 08:00:00 By Nasdaq GlobeNewswire